S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?

Athira Pharma (ATHA) Stock Price, News & Analysis

$2.74
+0.18 (+7.03%)
(As of 03/28/2024 ET)
Today's Range
$2.55
$2.83
50-Day Range
$2.24
$4.15
52-Week Range
$1.33
$4.30
Volume
578,095 shs
Average Volume
444,537 shs
Market Capitalization
$105.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.33

Athira Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
313.6% Upside
$11.33 Price Target
Short Interest
Healthy
2.77% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$390,211 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.86) to ($3.00) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.23 out of 5 stars

Medical Sector

402nd out of 938 stocks

Biological Products, Except Diagnostic Industry

62nd out of 153 stocks

ATHA stock logo

About Athira Pharma Stock (NASDAQ:ATHA)

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is ATH-1017 Fosgonimeton, a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an orally available, brain-penetrant small molecule positive modulator of HGF/MET which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

ATHA Stock Price History

ATHA Stock News Headlines

Athira Pharma, Inc. (ATHA)
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Athira Pharma Inc (ATHA)
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Athira Pharma's chief medical officer retires
BTIG Reaffirms Their Buy Rating on Athira Pharma (ATHA)
Optimistic Outlook for Athira Pharma Despite Setback: Buy Rating Affirmed
Athira Pharma Insiders Placed Bullish Bets Worth US$556.3k
Promising Progress and Robust Funding Drive Buy Rating for Athira Pharma
See More Headlines
Receive ATHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ATHA
Fax
N/A
Employees
65
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.33
High Stock Price Target
$19.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+313.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-117,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.42 per share

Miscellaneous

Free Float
32,616,000
Market Cap
$105.02 million
Optionable
Optionable
Beta
2.83
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Mark J. Litton M.B.A. (Age 56)
    Ph.D., President, CEO & Director
    Comp: $777.15k
  • Ms. Rachel P. Lenington M.B.A. (Age 50)
    Chief Development Officer & COO
    Comp: $578k
  • Mr. Andrew W. Gengos (Age 60)
    CFO & Chief Business Officer
  • Dr. Kevin Church Ph.D. (Age 39)
    Chief Scientific Officer
    Comp: $123.67k
  • Ms. Julie Rathbun
    Head of Investor Relations
  • Mr. Mark F. Worthington J.D. (Age 58)
    General Counsel & Corporate Secretary
    Comp: $503.83k
  • Ms. Samantha Willing
    Chief People Officer

ATHA Stock Analysis - Frequently Asked Questions

Should I buy or sell Athira Pharma stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athira Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATHA shares.
View ATHA analyst ratings
or view top-rated stocks.

What is Athira Pharma's stock price target for 2024?

2 brokerages have issued twelve-month price targets for Athira Pharma's shares. Their ATHA share price targets range from $5.00 to $19.00. On average, they expect the company's share price to reach $11.33 in the next twelve months. This suggests a possible upside of 313.6% from the stock's current price.
View analysts price targets for ATHA
or view top-rated stocks among Wall Street analysts.

How have ATHA shares performed in 2024?

Athira Pharma's stock was trading at $2.43 at the beginning of 2024. Since then, ATHA stock has increased by 12.8% and is now trading at $2.74.
View the best growth stocks for 2024 here
.

When is Athira Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ATHA earnings forecast
.

How were Athira Pharma's earnings last quarter?

Athira Pharma, Inc. (NASDAQ:ATHA) posted its earnings results on Thursday, February, 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.96) by $0.25.

What ETF holds Athira Pharma's stock?

Simplify Propel Opportunities ETF holds 1,492,792 shares of ATHA stock, representing 4.24% of its portfolio.

What other stocks do shareholders of Athira Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athira Pharma investors own include GW Pharmaceuticals (GWPH), Intel (INTC), Lumentum (LITE), NIO (NIO), NVIDIA (NVDA), Boeing (BA), Alibaba Group (BABA), Beyond Meat (BYND), Delta Air Lines (DAL) and Extreme Networks (EXTR).

When did Athira Pharma IPO?

Athira Pharma (ATHA) raised $160 million in an IPO on Friday, September 18th 2020. The company issued 10,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel served as the underwriters for the IPO and JMP Securities was co-manager.

Who are Athira Pharma's major shareholders?

Athira Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (14.10%), BML Capital Management LLC (3.82%), Pathstone Holdings LLC (0.98%), Dimensional Fund Advisors LP (0.91%), GSA Capital Partners LLP (0.79%) and Bridgeway Capital Management LLC (0.56%). Insiders that own company stock include Andrew Gengos, Glenna Mileson, Hans Moebius, James A Johnson, Kelly A Romano, Mark James Litton, Mark Worthington, Perceptive Advisors Llc and Rachel Lenington.
View institutional ownership trends
.

How do I buy shares of Athira Pharma?

Shares of ATHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ATHA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners